LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

Core Viewpoint - LIR Life Sciences Corp. has entered into a services agreement with Neuland Laboratories Limited to advance its transdermal GLP-1/GIP platform through R&D services [1] Group 1: Company Overview - LIR Life Sciences Corp. is focused on developing novel peptide formulations [1] - Neuland Laboratories Limited is a global contract development and manufacturing organization with over 40 years of experience in active pharmaceutical ingredient development [1] Group 2: Agreement Details - The R&D Agreement involves Neuland Labs providing research and development services to test and advance LIR's peptide formulations [1] - The collaboration aims to support LIR's transdermal GLP-1/GIP platform, which is significant for the company's product development strategy [1]